教职员工

快速导航

当前位置:首页 >> 教职员工 >> 教工信息
  • 姓  名:陈建忠
  • 职称职务:教授,博士生导师
  • 联系电话:0571-88208659
  • 电子邮箱:chjz@zju.edu.cn
  • 办公地址:浙江大学药学院,浙江杭州余杭塘路388号,邮编:310058
个人简介

研究方向:

计算机辅助药物设计和虚拟筛选;

构效关系和先导化合物的发现;

NMR研究药物分子生理作用机制;

理论计算酶催化分子机制研究

NMR药物筛选。

 

学历背景:

杭州大学理学学士(化学,1990)、中国科学院上海药物研究所理学硕士(有机化学,1993)、中国科学院上海药物研究所理学博士(有机化学,1996),美国康涅狄格大学哲学博士(Pharmaceutical Sciences,2005)。

 

国外学习与研究:

1998年~ 2001年:美国康涅狄格大学材料科学研究所(Institute of Material Sciences, University of Connecticut,USA)访问学者;

2001年~ 2005年:美国康涅狄格大学药学院(School of Pharmacy, University of Connecticut,USA)博士研究生;

2005年~ 2006 年:美国休斯顿大学药学院(College of Pharmacy, University of Houston,USA)博士后;

2006年~ 2008年:美国匹兹堡大学药学院(School of Pharmacy, University of Pittsburgh,USA)Res. Asso.。

 

工作经历:

1996年~ 1998年:中国科学院上海药物研究所,助理研究员;

2008年~ 2011:浙江大学药学院,研究员,博士生导师;

2012年~至今:浙江大学药学院,教授,博士生导师。

 

目前承担的主要研究项目:

1. 国家自然科学基金项目:新型大麻素CB2受体拮抗剂的药物设计、合成、和药理学评价(No. 30973637, 2010.01~2012.12, 项目负责人)

2. 国家“十一∙五”新药创制研究重大科技专项--新药研究开发关键技术:针对肿瘤、心脑血管等重大疾病的先导化合物结构优化设计的关键技术研究(2009.01~2010.12,课题副组长,浙江大学课题负责人)

3. 浙江省科技厅钱江人才计划:新型大麻素CB1受体拮抗剂的药物设计、合成、和药理学评价。项目编号:2010R10048,2010.8~2012.7,项目负责人。

4. 国家自然科学基金项目:基于NMR和计算模拟的II相代谢酶UGT代谢机制研究,项目编号:81172983,2012.01~2015.12,项目负责人

5. 浙江大学青年科研创新专项经费:新型大麻素CB2受体激动剂的药物设计、合成、和药理学评价,项目编号:5A7000-172210124,项目负责人

6. 国家自然科学基金项目:DJ-1蛋白抑制剂的分子设计、构效关系、生物活性测试及生物学作用机制研究,项目编号:81473135 ,2015.01~2018.12,项目负责人.

7. 新药研究国家重点实验室开放课题:基于复合物晶体结构的肿瘤因子DJ-1蛋白活性配体的药物设计、合成、和构效关系研究。项目编号:SIMM1501KF-02,课题负责人,2015.04~2016.05.

 

获奖情况:

稽汝运,陈凯先,蒋华良,陈建忠,等,基于蛋白质和核酸三维结构知识的药物设计,中国科学院自然科学二等奖

 

专利:

1. 发明人:陈建忠,何俏军,杨波,曹戟,潘有禄,韩爽。申请专利名:抑制DJ-1二聚化的活性化合物的应用。2014年,专利申请号:201410022128.8

2. 发明人:陈建忠,谢欣,韩爽,张菲菲。申请专利名:喹啉二酮类衍生物及其制备方法和用途。2013年,专利申请号:20130172266.X。

3. 发明人:陈建忠,谢欣,韩爽,张菲菲。申请专利名:3-取代香豆素类衍生物及其用途。2013年,专利申请号:20130171598.6。

4. 发明人:陈建忠,蒋超意,吴昊姝,何俏军,杨波. 一类新型DPP-IV抑制剂制备方法和用途。2012年,中国专利申请号:2012011300208410

5. Xiang-Qun Xie, Jian-Zhong Chen, Yuxun Zhang. LIGANDS SPECIFIC FOR CANNABINOID RECEPTOR SUBTYPE 2. 2009, PCT WO2009/058377A1

6. Xiang-Qun Xie, Jian-Zhong Chen, Yuxun Zhang. LIGANDS SPECIFIC FOR CANNABINOID RECEPTOR SUBTYPE 2. U.S. Provisional Patent Application USSN 60/984,461,2007

 

近年主要论著和(*通讯作者,总数50余篇SCI论文):

1. Shuang Han, Fei-Fei Zhang, Hai-Yan, Li-Li Chen, Xin Xie, Jian-Zhong Chen* Design, Syntheses, Structure-Activity Relationships and Docking Studies of Coumarin Derivatives as Novel Selective Ligands for the CB2 Receptor. Eur. J. Med. Chem, 2015, 93, 16-32.

2. T. A. Chohan, H. Qian, Y. Pan, J.-Z. Chen* Cyclin-dependent kinase-2 as a target for cancer therapy: Progress in the development of CDK2 inhibitors as anti-cancer agents. Curr. Med. Chem. 2015, 22, 237-263

3. Y. Cao, S. Han, L. Yu, H. Qian, J.-Z. Chen*. MD and QM/MM Studies on Long-Chain L‑α-Hydroxy Acid Oxidase:  Substrate Binding Features and Oxidation Mechanism. J. Phys. Chem. B 2014, 118, 5406−5417.

4. S. Han, J.-J. Chen, J.-Z. Chen* Latest Progress in the Identification of Novel Synthetic Ligands for the Cannabinoid CB2 Receptor Mini-Rev. Med. Chem., 2014, 14, 426-443.

5. Shuang Han, Fei-Fei Zhang, Xin Xie, Jian-Zhong Chen*, Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists. Eur. J. Med. Chem., 2014, 74, 73-84

6. Yang Cao, Zhong-Jian Chen, Hui-Di Jiang, and Jian-Zhong Chen*. Computational Studies of the Regioselectivities of COMT-Catalyzed Meta-/Para-O Methylations of Luteolin and Quercetin. J. Phys. Chem. B 2014, 118, 470−481

7. Lushan Yu, Jianbin Pu, Minjuan Zuo, Xia Zhang, Yang Cao, Shifeng Chen, Yan Lou, Quan Zhou Haihong Hu, Huidi Jiang, Jianzhong Chen*, and Su Zeng*. Hepatic Glucuronidation of Isoneochamaejasmin A from the Traditional Chinese Medicine Stellera Chamaejasme L. Root. Drug Metab. Dispos. 2014, 42:1–9.

8. Shi-Feng Chen, Yang Cao, Shuang Han, Jian-Zhong Chen*  Insight into the structural mechanism for PKB _ allosteric inhibition by molecular dynamics simulations and free energy calculations. J. Mol. Graph. Model. 48 (2014) 36–46

9. Shi-Feng Chen & Yang Cao & Jiong-Jiong Chen, Jian-Zhong Chen*.  Binding selectivity studies of PKBαusing molecular dynamics simulation and free energy calculations. J. Mol. Model. 2013, 19:5097-5112,

10. Shifeng Chen, Jianzhong Chen*, Development for anticancer therapy small-molecule inhibitors targeting protein kinase B. Mini-Rev. Med. Chem.,2013, 23:1272-1294,

11. Jiong-Jiong chen, Shuang Han, Yang Cao, Jian-Zhong Chen*,The agonist binding mechanism of human CB2 receptor studied by molecular dnamics simulation, free energy calculation and 3D-QSAR studies, 药学学报2013,48:1436-1449,

12. Lili Ou, Shuang Han, Wenbo Ding, Zhe Chen, Ziqi Ye, Hongyu Yang, Goulin Zhang, Yijia Lou, Jian-Zhong Chen*, Yongping Yu*. Design, synthesis and 3D-QSAR study of cytotoxic flavonoid derivatives, Mol. Diver. 2011, 15:665–675.

13. Lili Ou, Shuang Han, Wenbo Ding, Ping Jia, Bo Yang, Jose L. Medina-Franco, Marc A. Giulianotti, Jian-Zhong Chen*, Yongping Yu*, Parallel synthesis of novel antitumor agents: 1,2,3-triazoles bearing biologically active sulfonamide moiety and their 3D-QSAR. Mol. Diver.  2011, 15:927–946.

14. Chaoyi Jiang, Shuang Han, Tiegang Chen, Jianzhong Chen*. 3D-QSAR and docking studies of arylmethylamine-based DPP IV inhibitors Acta Pharmaceutica Sinica B 2012, 2(4):411–420

15. J.-Z. Chen, K.-Z. Myint, X.-Q. Xie, New QSAR prediction models derived from GPCR CB2-antagonistic triaryl bis-sulfone analogues by a combined molecular morphological and pharmacophoric approach. SAR and QSAR in Environmental Research. (2011), 22(5-6): 525–544.

16. 刘瑶, 洪岚, 余露山, 蒋惠娣, 陈建忠, 孟琴, 陈枢青, 曾苏,创新药物转化研究中ADME 的评价,药学学报,2011, 46 (1): 19-29

17. Jurg Gertsch, Marco Leonti, Stefan Raduner, Ildiko Racz, Jian-Zhong Chen, Xiang-Qun Xie, Karl-Heinz Altmann, Meliha Karsak, and Andreas Zimmer, Beta-caryophyllene is a dietary cannabinoid. PNAS, 2008, 105: 9099-9014

18. Xiang-Qun Xie, Jian-Zhong Chen, Data-Mining Representative Small Molecule Drug Screening Database from NIH PubChem. Journal of Chemical Infomatics and Modeling, 2008, 48: 465-475.

19. Shuli Mao, Donald Probst, Stefan Werner, Jian-Zhong Chen, Xiangqun Xie, and Kay M. Brummond Diverging Rh(I)-Catalyzed Carbocylization Strategy to Prepare a Library of Unique Cyclic Ethers.J. Comb. Chem., 2008, 10: 235-246.

20. Jian-Zhong Chen, Junmei Wang, Xiang-Qun Xie. GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search. J. Chem. Info. Modeling, 2007, 47(4), 1626-1637.

21. Stefan Raduner, Adriana Majewska, Jian-Zhong Chen, Xiang-Qun Xie, Jacques Hamon, Bernard Faller, Karl-Heinz Altmann, Jürg Gertsch. Alkylamides from Echinacea are a new class of cannabinomimetics. CB2-RECEPTOR DEPENDENT AND INDEPENDENT IMMUNOMODULATORY EFFECTS. Journal of Biological Chemistry,2006, 281(20), 14192-14206.

22. Jian-Zhong Chen, Xiu-Wen Han, Qian Liu, Alexandros Makriyannis, Junmei Wang, and Xiang-Qun Xie. 3D QSAR Studies of Arylpyrazole Antagonists of CB1 and CB2 Cannabinoid Receptors. A Combined NMR and CoMFA Approach. Journal of Medicinal Chemistry,2006, 49(2), 625-636.

23. Jian-Zhong Chen, Shrirang V. Ranade, Xiang-Qun Xie. NMR characterization of paclitaxel/poly (styrene-isobutylene-styrene) formulations. International Journal of Pharmaceutics, 2005, 305(1/2), 129-144

24. Xiang-Qun Xie, Jian-Zhong Chen. NMR structural comparison of the cytoplasmic juxtamembrane domains of G-protein coupled CB1 and CB2 receptors in membrane-mimetic DPC micelles. Journal of Biological Chemistry,2005, 280(5), 3605-3612.

25. Jian-Zhong Chen, Xiu-Wen Han, Xiang-Qun Xie. Preferred conformations of endogenous cannabinoid ligand anandamide. Life Sciences, 2005, 76: 2053-2069

26. Haihu Qin, Brian J. Chakulski, Ingrid A. Rousseau, Jian-Zhong Chen, Xiang-Qun Xie, Patrick T. Mather, Gregory S. Constable, Bryan E. Coughlin.  Synthesis and characterization of unsaturated thermotropic polyesters prepared via acyclic diene metathesis polymerization. Macromolecules ,2004,37(14):5239-5249. 

27. Xiang-Qun Xie, Jian-Zhong Chen, Eric M Billing. 3D structural model of the G-protein coupled cannabinoid CB2 receptor. Proteins ,2003, 53: 307- 319